Abbott India Limited: Business Overview, Financials & Competitive Analysis
Abbott India Limited scores 7/10 on the AskCyborg Cyborg Score (Strong). Stable, profitable Indian pharma leader with strong returns and dividend potential, though constrained by modest revenue growth. With a market cap of $7.01B and strong fundamentals including zero debt, Abbott India demonstrates solid operational strength and returns to shareholders. However, the company has delivered poor sales growth of 9.38%.
What is Abbott India Limited's industry? Abbott India Limited (abbott.co.in) operates in Pharmaceuticals and Healthcare - Drug Manufacturers (Specialty & Generic). AskCyborg classifies Abbott India Limited under Pharmaceuticals and Healthcare - Drug Manufacturers (Specialty & Generic) in its company registry.
Abbott India is a pharmaceutical company offering diagnostics, medical devices, nutritionals, and branded generic pharmaceuticals, with focus on women's health, gastroenterology, and hepatic care. The company is one o...
Cyborg Score thesis
Stable, profitable Indian pharma leader with strong returns and dividend potential, though constrained by modest revenue...
Read the full analyst-debate transcript →Get the Latest Abbott India Limited Report
Up-to-date AI-powered research, analyst debate audio & saved-company playlists
Get Current Report FreeAbbott India Limited Overview
Pro stress-test →Abbott India is a pharmaceutical company offering diagnostics, medical devices, nutritionals, and branded generic pharmaceuticals, with focus on women's health, gastroenterology, and hepatic care. The company is one of the leading multinational pharmaceutical companies in India and sells products primarily within India through independent distributors.
Strategic Profile
Pro stress-test →As a subsidiary of Abbott Laboratories, the company develops and distributes science-based products across diverse therapeutic areas including women's health, gastroenterology, cardiology, metabolic disorders, and primary care. The company is almost debt-free with strong profitability, delivering 19.0% profit growth CAGR over five years and maintaining a healthy dividend payout of 72.2%.
Competitive Landscape
Pro stress-test →Abbott India competes with major multinational and Indian pharmaceutical players including Boehringer Ingelheim, Johnson & Johnson, Novo Nordisk, Novartis, and Merck & Co. The company holds a strong position in India's branded generic and specialty pharmaceutical segments, competing on product quality, distribution networks, and therapeutic focus areas.
Industry Context
Abbott India Limited operates in Pharmaceuticals and Healthcare - Drug Manufacturers (Specialty & Generic).
Key facts
Founded: 1944 · Headquarters: Mumbai, India · Employees: 3,659 · Revenue: $766M · Market cap: $7.01B